UNSPSC 51111756: Ofatumumab

This classification denotes a monoclonal antibody with the molecular formula C6480H10022N1742O2020S44, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier M95KG522R0, more generally known as ofatumumab. European Medicines Agency schedules ofatumumab in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB25221. The term OFATUMUMAB is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 20, no. 1, 2006, list 55.

OFATUMUMAB is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule Ofatumumab under HS 30021091 and SITC 54163. SMILES:. As of Q4 2014, OFATUMUMAB remains the US FDA Preferred Term for this commodity.. Ofatumumab bears US NLM identifiers UMLS ID C1832027 and NCI Concept Code C66952.

UNSPSC 51111756 Ofatumumab, a Commodity code, nominally covers a specific monoclonal antibody therapy, but recent state and local procurement activity under this code shows little alignment with the product itself. The posted opportunities span medical and pharmaceutical supplies procurement broadly—naloxone and drug deactivation systems for emergency response, generic multi-source pharmaceuticals distributed through wholesalers, first aid supplies for fire rescue operations, and exploratory direct-to-manufacturer prescription program capabilities—rather than ofatumumab as a named therapeutic. Issuing bodies include county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission, Minnesota Department of Administration), municipal fire departments (City of Tampa Fire Department), and cooperative purchasing organizations serving multi-state and multi-jurisdictional government networks (MMCAP). The disparity between the code's nominal scope and the actual solicitation subjects suggests either broad tagging of pharmaceutical procurement across the UNSPSC taxonomy or administrative misclassification by the issuing bodies.

Recent activity clusters in Florida, Texas, and Minnesota. Seminole County posted an IFB on June 30, 2026, for 1,900 units of naloxone and 800 drug deactivation systems annually with a July 26, 2023, response deadline (note: date discrepancy in source). The City of Tampa issued an ITB (Bid Number 26-P-00145) on March 25, 2026, for medical and first aid supplies including respiratory equipment and cardiac monitoring devices, with an estimated contract value of $700,000 and a March 13, 2026, response deadline, designated as a sheltered market opportunity for certified Small Local Business Enterprises with a 5 percent bid discount. The Texas HHS Commission released an RFI on April 3, 2026, regarding direct-to-manufacturer prescription fulfillment capabilities. Minnesota's MMCAP issued an RFP with a March 26, 2026, response deadline for generic pharmaceuticals and OTC products to be distributed through three authorized wholesalers, with contract effectiveness on July 1, 2026. Given the mismatch between the code name and the procurement activities posted under it, this code shows limited decision-relevant activity for vendors pursuing ofatumumab-specific contracting.